Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 2025 Financial Results

Stock Track11-14

Shares of Trevi Therapeutics, Inc. (TRVI) plunged 5.57% in intraday trading following the release of the company's third-quarter 2025 financial results. The biopharmaceutical firm, which focuses on developing treatments for chronic cough and pruritus, reported figures that fell short of investor expectations, triggering a sell-off in the stock.

According to the company's financial report, Trevi Therapeutics posted a net loss of $11.802 million for the quarter, with earnings per share (EPS) coming in at -$0.08. The firm's operating expenses reached $13.916 million, resulting in a negative income from operations of $13.916 million. These figures highlight the ongoing challenges faced by the company in its pursuit of bringing new therapies to market.

The substantial net loss and negative EPS have raised concerns among investors about Trevi's financial health and its ability to fund ongoing research and development efforts. As a result, the stock experienced significant downward pressure during the trading session. While the company also provided business updates alongside its financial results, the market's focus appears to be primarily on the bottom-line figures, which have prompted a reassessment of Trevi's near-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152590401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152590401","market":"us","top_or_hot":-1,"title":"Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 2025 Financial Results","media":"Stock Track","content":"<p>Shares of Trevi Therapeutics, Inc. (TRVI) plunged 5.57% in intraday trading following the release of the company's third-quarter 2025 financial results. The biopharmaceutical firm, which focuses on developing treatments for chronic cough and pruritus, reported figures that fell short of investor expectations, triggering a sell-off in the stock.</p>\n\n<p>According to the company's financial report, Trevi Therapeutics posted a net loss of $11.802 million for the quarter, with earnings per share (EPS) coming in at -$0.08. The firm's operating expenses reached $13.916 million, resulting in a negative income from operations of $13.916 million. These figures highlight the ongoing challenges faced by the company in its pursuit of bringing new therapies to market.</p>\n\n<p>The substantial net loss and negative EPS have raised concerns among investors about Trevi's financial health and its ability to fund ongoing research and development efforts. As a result, the stock experienced significant downward pressure during the trading session. While the company also provided business updates alongside its financial results, the market's focus appears to be primarily on the bottom-line figures, which have prompted a reassessment of Trevi's near-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 2025 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Trevi Therapeutics Plummets 5.57% Following Disappointing Q3 2025 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Trevi Therapeutics, Inc. (TRVI) plunged 5.57% in intraday trading following the release of the company's third-quarter 2025 financial results. The biopharmaceutical firm, which focuses on developing treatments for chronic cough and pruritus, reported figures that fell short of investor expectations, triggering a sell-off in the stock.</p>\n\n<p>According to the company's financial report, Trevi Therapeutics posted a net loss of $11.802 million for the quarter, with earnings per share (EPS) coming in at -$0.08. The firm's operating expenses reached $13.916 million, resulting in a negative income from operations of $13.916 million. These figures highlight the ongoing challenges faced by the company in its pursuit of bringing new therapies to market.</p>\n\n<p>The substantial net loss and negative EPS have raised concerns among investors about Trevi's financial health and its ability to fund ongoing research and development efforts. As a result, the stock experienced significant downward pressure during the trading session. While the company also provided business updates alongside its financial results, the market's focus appears to be primarily on the bottom-line figures, which have prompted a reassessment of Trevi's near-term prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRVI","symbol_name":"Trevi Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1152590401","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152590401","pubTimestamp":1763068112,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Trevi Therapeutics, Inc. (TRVI) plunged 5.57% in intraday trading following the release of the company's third-quarter 2025 financial results. The biopharmaceutical firm, which focuses on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRVI":"Trevi Therapeutics Inc."},"translate_title":"股票追踪|Trevi Therapeutics在令人失望的2025年第三季度财务业绩后暴跌5.57%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRVI":1},"content_text":"Shares of Trevi Therapeutics, Inc. (TRVI) plunged 5.57% in intraday trading following the release of the company's third-quarter 2025 financial results. The biopharmaceutical firm, which focuses on developing treatments for chronic cough and pruritus, reported figures that fell short of investor expectations, triggering a sell-off in the stock.\nAccording to the company's financial report, Trevi Therapeutics posted a net loss of $11.802 million for the quarter, with earnings per share (EPS) coming in at -$0.08. The firm's operating expenses reached $13.916 million, resulting in a negative income from operations of $13.916 million. These figures highlight the ongoing challenges faced by the company in its pursuit of bringing new therapies to market.\nThe substantial net loss and negative EPS have raised concerns among investors about Trevi's financial health and its ability to fund ongoing research and development efforts. As a result, the stock experienced significant downward pressure during the trading session. While the company also provided business updates alongside its financial results, the market's focus appears to be primarily on the bottom-line figures, which have prompted a reassessment of Trevi's near-term prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152590401","isCrawlerRequest":true}